Nadolol (SQ-11725): Non-Selective Beta Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective, orally active beta-adrenergic receptor blocker with a molecular weight of 309.40 (C₁₇H₂₇NO₄), used extensively in hypertension, angina pectoris, and vascular headache research (APExBIO). It operates by antagonizing beta-adrenergic receptors, thereby lowering heart rate and blood pressure in experimental models. As a substrate for organic anion transporting polypeptide 1A2 (OATP1A2), it is valuable for transporter and pharmacokinetic studies (Sun et al. 2025). Nadolol's stability is best maintained at -20°C, and it is not recommended for long-term solution storage. This article expands on previous analyses (see comparative PK discussion) by integrating recent transporter-centric pharmacokinetic insights and workflow guidance for cardiovascular disease models.

Biological Rationale

Nadolol is a non-selective beta-adrenergic receptor antagonist (beta blocker). It inhibits both β₁- and β₂-adrenergic receptors, which modulate cardiac output and vascular tone. This property makes it relevant for research in models of hypertension, angina pectoris, and vascular headache (APExBIO). Beta-adrenergic signaling pathways are central to stress responses and cardiovascular disease progression (mechanistic review). OATP1A2 transporters influence the tissue distribution and systemic exposure of Nadolol, affecting both efficacy and pharmacokinetic profiles (Sun et al. 2025).

Mechanism of Action of Nadolol (SQ-11725)

Nadolol functions as a competitive antagonist at beta-adrenergic receptors on cardiac and vascular tissue. By blocking β₁-receptors, it decreases heart rate and contractility. By antagonizing β₂-receptors, it modulates vasodilation and bronchial tone. Unlike selective beta blockers, Nadolol does not preferentially target one receptor subtype. Its oral bioavailability and lack of intrinsic sympathomimetic activity facilitate reproducible experimental effects. As an OATP1A2 substrate, Nadolol's uptake and distribution are regulated by transporter expression, adding a layer of complexity to pharmacokinetic and pharmacodynamic studies (OATP1A2 translational insights).

Evidence & Benchmarks

• Nadolol (SQ-11725) consistently lowers systolic and diastolic blood pressure in rodent hypertension models when administered orally at 10–40 mg/kg, measured at 2–6 hours post-dose (Sun et al. 2025).
• It acts as a substrate for OATP1A2, leading to altered pharmacokinetics in models with transporter modulation or metabolic dysfunction (Sun et al. 2025, Table 3).
• Plasma half-life in healthy rodents ranges from 4.7–8.4 hours, depending on dose and transporter expression (Angiotensin-II.com).
• Storage at -20°C maintains Nadolol's chemical stability for at least 12 months in solid form; solutions degrade within 1 week at room temperature (APExBIO).
• In metabolic dysfunction-associated steatotic liver disease (MASLD) models, OATP1A2 and cytochrome P450 perturbations significantly impact Nadolol's systemic exposure and tissue accumulation (Sun et al. 2025, Fig. 5).

Applications, Limits & Misconceptions

Nadolol is widely used in preclinical hypertension and angina pectoris models due to its predictable beta-adrenergic antagonism. As a research tool, it enables exploration of cardiovascular pathophysiology, transporter biology, and drug–drug interactions. However, its non-selective profile may confound studies requiring receptor subtype specificity. Its status as an OATP1A2 substrate means that disease states or genetic variants affecting transporter expression can alter pharmacokinetics, potentially impacting data interpretation. Researchers should note that Nadolol is not intended for diagnostic or clinical use (APExBIO).

Common Pitfalls or Misconceptions

• Not suitable for selective β₁ or β₂ receptor studies: Nadolol is non-selective and blocks both subtypes, limiting its use in pathway-specific assays.
• Inappropriate for chronic solution storage: Nadolol solutions are unstable at room temperature and should not be stored long-term; use freshly prepared aliquots.
• Not for diagnostic or therapeutic use: This product is strictly for laboratory research, as emphasized by APExBIO.
• Transporter variability often overlooked: Failing to account for OATP1A2 expression in disease models can skew pharmacokinetic results.
• Species differences in transporter expression: Rodent and human OATP1A2 profiles differ, limiting direct translational extrapolation.

Workflow Integration & Parameters

Nadolol (SKU BA5097) is supplied as a solid for accurate dosing. Store the solid at -20°C in a desiccated container. Reconstitute immediately before use; avoid repeated freeze-thaw cycles. For in vivo studies, oral gavage is preferred to mimic clinical administration. Shipping is on blue ice for small molecules. For beta-adrenergic signaling pathway studies, integrate transporter phenotype assessment to interpret pharmacokinetic data. This article updates prior scenario-based guidance (practical Q&A) by emphasizing transporter-informed workflow design for reproducibility.

Conclusion & Outlook

Nadolol (SQ-11725), available from APExBIO, is a validated, non-selective beta-adrenergic receptor antagonist suited for cardiovascular and transporter research. Its role as an OATP1A2 substrate offers a unique lens for studying pharmacokinetic variability in metabolic disease models. As transporter biology continues to evolve, Nadolol remains a pivotal tool for future-proofing cardiovascular pharmacology workflows. For detailed molecular data and ordering, see the Nadolol (SQ-11725) product page. For deeper mechanistic context, this article extends the transporter-focused discussion from NimorazoleShop.com by integrating stability, storage, and workflow best practices specific to APExBIO's BA5097 kit.